Pharma Research (KRX: 214450)
Who is buying Pharma Research?
Between Sep 15, 2026 and Oct 16, 2026 (20 trading sessions), foreign investors net bought ₩130.1bn ($97M) of Pharma Research, the 3rd largest foreign net purchase among 1828 KOSDAQ stocks. Institutions net sold ₩126.2bn ($94M) and retail investors net sold ₩1.3bn ($1M) over the same window. Foreigners were net buyers on 14 of the 20 sessions.
Foreign investors hold 15.69% of Pharma Research's listed shares (KRX ownership data as of Oct 16, 2026), up from 11.98% twenty sessions earlier and 20.64% a year ago.
The stock closed at ₩278,000 on Oct 16, 2026: -19.54% over 20 sessions, -31.02% year-to-date, -50.62% over one year. The 52-week range is ₩251,500 – ₩606,000.
At ₩278,000 the stock trades at 11.95× 12-month-forward consensus earnings (12 analysts), 11.53× on FY2027 estimates. The trailing P/E published by KRX is 17.49×, based on the last completed fiscal year.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-16 | ₩278,000 | ₩-0.8bn | +₩6.5bn | ₩-6.2bn |
| 2026-10-15 | ₩258,500 | +₩26.4bn | ₩-4.6bn | ₩-20.4bn |
| 2026-10-14 | ₩271,000 | +₩3.9bn | ₩-4.5bn | +₩0.4bn |
| 2026-10-13 | ₩273,000 | +₩17.1bn | ₩-23.7bn | +₩6.9bn |
| 2026-10-12 | ₩297,000 | +₩6.5bn | +₩1.9bn | ₩-8.4bn |
| 2026-10-08 | ₩302,500 | +₩8.3bn | ₩-8.1bn | ₩-0.2bn |
| 2026-10-07 | ₩308,500 | +₩2.6bn | ₩-4.0bn | +₩0.3bn |
| 2026-10-06 | ₩306,000 | +₩11.6bn | ₩-7.7bn | ₩-3.0bn |
| 2026-10-02 | ₩306,000 | ₩-3.3bn | ₩-11.5bn | +₩15.2bn |
| 2026-10-01 | ₩314,500 | +₩12.5bn | ₩-13.9bn | +₩1.4bn |
| 2026-09-30 | ₩310,500 | +₩10.7bn | ₩-18.0bn | +₩7.7bn |
| 2026-09-29 | ₩316,500 | +₩9.2bn | ₩-4.6bn | ₩-4.3bn |
| 2026-09-28 | ₩320,000 | ₩-1.1bn | +₩0.3bn | +₩0.5bn |
| 2026-09-23 | ₩322,500 | +₩1.0bn | ₩-0.6bn | ₩-0.3bn |
| 2026-09-22 | ₩324,000 | ₩-2.8bn | +₩2.0bn | +₩0.9bn |
| 2026-09-21 | ₩325,000 | +₩5.9bn | ₩-6.2bn | +₩0.3bn |
| 2026-09-18 | ₩327,500 | +₩5.3bn | ₩-10.1bn | +₩4.7bn |
| 2026-09-17 | ₩329,500 | ₩-0.7bn | ₩-4.8bn | +₩5.3bn |
| 2026-09-16 | ₩331,000 | +₩18.0bn | ₩-14.1bn | ₩-3.8bn |
| 2026-09-15 | ₩337,000 | ₩-0.3bn | ₩-0.6bn | +₩1.6bn |
| 2026-09-14 | ₩345,500 | ₩-2.2bn | +₩1.7bn | +₩0.7bn |
| 2026-09-11 | ₩342,000 | +₩15.0bn | ₩-16.9bn | +₩2.1bn |
| 2026-09-10 | ₩349,500 | +₩17.2bn | ₩-27.3bn | +₩10.7bn |
| 2026-09-09 | ₩366,000 | +₩27.0bn | ₩-37.4bn | +₩10.9bn |
| 2026-09-08 | ₩369,000 | +₩10.7bn | ₩-12.7bn | +₩4.0bn |
| 2026-09-07 | ₩376,500 | +₩4.1bn | ₩-6.9bn | +₩5.0bn |
| 2026-09-04 | ₩386,500 | ₩-0.8bn | +₩3.5bn | ₩-1.8bn |
| 2026-09-03 | ₩381,000 | +₩14.9bn | ₩-4.0bn | ₩-10.9bn |
| 2026-09-02 | ₩392,500 | +₩10.2bn | ₩-5.4bn | ₩-4.5bn |
| 2026-09-01 | ₩414,000 | +₩1.2bn | ₩-12.4bn | +₩12.2bn |
| 2026-08-31 | ₩426,000 | ₩-22.2bn | ₩-10.3bn | +₩29.8bn |
| 2026-08-28 | ₩461,500 | +₩28.9bn | +₩10.9bn | ₩-39.4bn |
| 2026-08-27 | ₩432,500 | ₩-3.6bn | ₩-1.2bn | +₩5.0bn |
| 2026-08-26 | ₩442,000 | +₩21.7bn | +₩12.6bn | ₩-32.6bn |
| 2026-08-25 | ₩414,500 | ₩-1.7bn | +₩0.0bn | +₩1.7bn |
| 2026-08-24 | ₩416,000 | +₩7.1bn | +₩7.0bn | ₩-13.2bn |
| 2026-08-21 | ₩400,500 | +₩3.9bn | ₩-7.7bn | +₩4.0bn |
| 2026-08-20 | ₩413,500 | +₩33.8bn | ₩-0.8bn | ₩-32.9bn |
| 2026-08-19 | ₩391,000 | +₩9.6bn | ₩-1.3bn | ₩-8.0bn |
| 2026-08-18 | ₩393,000 | +₩34.8bn | ₩-15.6bn | ₩-18.5bn |
| 2026-08-14 | ₩398,000 | +₩0.4bn | ₩-26.9bn | +₩25.7bn |
| 2026-08-13 | ₩425,500 | +₩36.1bn | ₩-12.4bn | ₩-21.6bn |
| 2026-08-12 | ₩408,000 | +₩11.1bn | ₩-8.6bn | ₩-0.5bn |
| 2026-08-11 | ₩417,000 | ₩-4.7bn | +₩7.3bn | ₩-2.5bn |
| 2026-08-10 | ₩410,000 | +₩31.3bn | +₩16.0bn | ₩-45.0bn |
| 2026-08-07 | ₩378,500 | ₩-22.2bn | +₩1.0bn | +₩20.9bn |
| 2026-08-06 | ₩394,500 | ₩-4.6bn | +₩11.5bn | ₩-8.9bn |
| 2026-08-05 | ₩378,000 | +₩37.1bn | ₩-14.2bn | ₩-21.7bn |
| 2026-08-04 | ₩384,500 | ₩-1.1bn | ₩-0.9bn | +₩2.1bn |
| 2026-08-03 | ₩372,000 | +₩8.4bn | +₩17.0bn | ₩-26.0bn |
| 2026-07-31 | ₩338,500 | +₩16.3bn | ₩-27.2bn | +₩11.2bn |
| 2026-07-30 | ₩348,000 | +₩0.8bn | +₩2.6bn | ₩-2.9bn |
| 2026-07-29 | ₩391,000 | ₩-32.3bn | +₩84.4bn | ₩-50.8bn |
| 2026-07-28 | ₩375,500 | ₩-56.3bn | +₩90.5bn | ₩-37.4bn |
| 2026-07-27 | ₩370,000 | ₩-11.3bn | +₩24.2bn | ₩-11.8bn |
| 2026-07-24 | ₩357,000 | ₩-2.9bn | +₩8.1bn | ₩-5.8bn |
| 2026-07-23 | ₩360,000 | +₩15.4bn | +₩16.7bn | ₩-32.0bn |
| 2026-07-22 | ₩322,500 | ₩-2.3bn | ₩-7.8bn | +₩10.1bn |
| 2026-07-21 | ₩341,500 | ₩-0.2bn | +₩9.1bn | ₩-8.9bn |
| 2026-07-20 | ₩327,000 | +₩5.1bn | +₩0.7bn | ₩-4.7bn |
| 2026-07-16 | ₩336,500 | ₩-1.9bn | +₩7.3bn | ₩-7.7bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | ₩-0.8bn | $-1M | +₩6.5bn | ₩-6.2bn |
| 5 days | +₩53.2bn | +$40M | ₩-24.4bn | ₩-27.7bn |
| 20 days | +₩130.1bn | +$97M | ₩-126.2bn | ₩-1.3bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying Pharma Research stock?
Over the last 5 sessions foreign investors net bought ₩53.2bn ($40M) of Pharma Research; over 60 sessions they net bought ₩363.9bn ($270M); since Jan 1, 2026 they net sold ₩264.3bn ($196M). Over 20 sessions the stock is the 3rd largest foreign net purchase among 1828 KOSDAQ stocks.
How much of Pharma Research do foreign investors own?
Foreign investors own 15.69% of Pharma Research's shares as of Oct 16, 2026, versus 20.64% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions net sold ₩126.2bn ($94M) and retail investors net sold ₩1.3bn ($1M) of Pharma Research. Foreign buying is being met mainly by retail selling.
Is Pharma Research listed on KOSPI or KOSDAQ?
Pharma Research (파마리서치) trades on KOSDAQ under KRX code 214450 in the Biotech & Pharma group, with a market capitalization of ₩3T ($2.1B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.
Annual financials
| Fiscal year | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| 2023 | ₩261bn ($194M) | – | ₩92bn ($69M) | ₩77bn ($57M) |
| 2024 | ₩350bn ($260M) | +34.10% | ₩126bn ($94M) | ₩89bn ($66M) |
| 2025 | ₩536bn ($398M) | +53.20% | ₩214bn ($159M) | ₩168bn ($125M) |
Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1345.9/$) for reference only.